EVALUASI PENGGUNAAN OBAT PADA PASIEN DISPEPSIA MENGGUNAKAN METODE ATC/DDD DI RUMAH SAKIT ROYAL PRIMA TAHUN 2022

Rachel Epifanes  Hutabarat; Daimah Wirdatus Sananun  Harahap; Astriani Natalia Br  Ginting

doi:10.36805/jbf.v6i1.1677

Rachel Epifanes Hutabarat Bachelor of Clinical Pharmacy, Faculty of Health Science, Universitas Prima Indonesia, Medan, 20118, Indonesia
Daimah Wirdatus Sananun Harahap Departement of Clinical Pharmacy, Faculty of Health Science, Universitas Prima Indonesia, Medan, 20118, Indonesia
Astriani Natalia Br Ginting PUI Phyto Degenerative & Lifestyle Medicine, Universitas Prima Indonesia

DOI: https://doi.org/10.36805/jbf.v6i1.1677

Keywords: Dyspepsia, ATC/DDD, DU90%, Rational Drug Use

Abstract

Dyspepsia is a common non-communicable disease that requires pharmacotherapy management according to clinical guidelines. Evaluation of drug use can be conducted using the ATC/DDD (Anatomical Therapeutic Chemical/Defined Daily Dose) and DU90% (Drug Utilization 90%) methods to describe prescribing patterns in healthcare facilities. This study aimed to evaluate drug use in dyspepsia patients at Royal Prima Hospital Medan in 2022 using a retrospective descriptive design using medical records of 180 patients from January–December 2022. Drugs were classified based on the WHO 2023 ATC system and analyzed using DDD calculations and the DU90% method. The results showed that four drugs included in the DU90% segment were omeprazole (tablets and injections) and ranitidine (tablets and injections), with a total contribution of 90.4% of the total DDD. The pattern of drug use is dominated by proton pump inhibitors and H₂ receptor antagonists, which are the main therapies in the management of dyspepsia based on the 2022 National Consensus on the Management of Dyspepsia and Helicobacter pylori Infection, so that the distribution of drug use obtained in this study shows compliance with national therapy recommendations.

References

Agustianingsih, P. D. (2023). Analisis penggunaan antibiotik pada pasien dispepsia di RSUD Prof. Dr. Margono Soekarjo dengan metode ATC/DDD dan DU 90%. Journal of Nursing & Health, 2013, 1–8.

Andrawes, M., et al. (2025). Proton pump inhibitors (PPIs): An evidence-based review of indications, efficacy, harms, and deprescribing. Medicina, 61(9). https://doi.org/10.3390/medicina61091569

Camilleri, M., & Bharucha, A. E. (2023). Diabetic gastroparesis. In StatPearls. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK430794/

Dm, M. F., & Permana, D. (2020). Penggunaan obat anti mual dan muntah pada pasien mual dan muntah di Puskesmas Karang Rejo Kota Tarakan. [Nama Jurnal Tidak Dicantumkan], 1(2), 61–68.

Ford, A. C., et al. (2020). Functional dyspepsia. The Lancet, 396(10263), 1689–1702. https://doi.org/10.1016/S0140-6736(20)30469-4

Guo, H., et al. (2025). Prevalence and association of functional dyspepsia in elderly patients: A systematic review and meta-analysis. The Aging Male, 28(1). https://doi.org/10.1080/13685538.2025.2511801

Hanifah, S., Melyani, I., & Madalena, L. (2022). Evaluasi penggunaan antibiotik dengan metode ATC/DDD dan DU90% pada pasien rawat inap kelompok staf medik penyakit dalam di salah satu rumah sakit swasta di Kota Bandung. Farmaka, 20(1), 21–26.

Lapina, T. L., & Ivashkin, V. T. (2023). Rebamipide during chronic gastritis: H. pylori eradication therapy and restoration of gastric mucosa barrier function. [Nama Jurnal Tidak Dicantumkan], 33(6), 81–86.

Natalia, A., et al. (2025). Antidiabetic activity of Cep-Cepan leaf extract nanoparticles (Castanopsis costata) in streptozotocin-induced white rat models. Jurnal Penelitian Pendidikan IPA, 11(2), 64–70. https://doi.org/10.29303/jppipa.v11i2.9408

Ndun, E. A. (2024). Faktor risiko kejadian dispepsia pada masyarakat usia 15–64 tahun di Kelurahan Oesao wilayah kerja. [Nama Jurnal Tidak Lengkap], 13(1), 37–49. https://doi.org/10.37048/kesehatan.v13i1.299

Purnamasari, L. (2017). Faktor risiko, klasifikasi, dan terapi sindrom dispepsia. Cermin Dunia Kedokteran, 44(12), 870–873.

Sari, K., et al. (2025). Treatment patterns of dyspepsia patients (ICD-10: K30) at outpatient care of X General Hospital. [Nama Jurnal Tidak Dicantumkan], 35–40.

Shibli, F., Kitayama, Y., & Fass, R. (2020). Novel therapies for gastroesophageal reflux disease: Beyond proton pump inhibitors. Current Gastroenterology Reports, 22(4), 16. https://doi.org/10.1007/s11894-020-0753-y

Sidik, A. J. (2024). Diagnosis dan tata laksana dispepsia. Cermin Dunia Kedokteran, 51(3), 140–144. https://doi.org/10.55175/cdk.v51i3.926

Syam, A. F., et al. (2023). Management of dyspepsia and Helicobacter pylori infection: The 2022 Indonesian consensus report. Gut Pathogens, 15, 1–19. https://doi.org/10.1186/s13099-023-00551-2

Sylvia Puspita. (2025). Evaluasi penggunaan obat PPI (proton pump inhibitor) pada pasien rawat inap di RSAU dr. Efram Harsana Lanud Iswahjudi Magetan. Jurnal Pengembangan Ilmu dan Praktik Kesehatan, 4, 220–231.

Twenty, N., et al. (2025). Evaluasi penggunaan obat dan identifikasi drug related problems (DRPs) pada pasien rawat inap diabetes melitus tipe 2 di Rumah Sakit Umum Royal Prima Marelan. [Nama Jurnal Tidak Dicantumkan], 1, 85–93.

Wirdatus, D., et al. (2024). Medication adherence among drug-resistant tuberculosis (DR-TB) patients at Universitas Indonesia Hospital. Jurnal Respirologi Indonesia, 44(3).

You, S. C., et al. (2023). Ranitidine use and incident cancer in a multinational cohort. JAMA Network Open, 6(9), e2333495. https://doi.org/10.1001/jamanetworkopen.2023.33495

Zakiyah, W., et al. (2021). Definisi, penyebab, klasifikasi, dan terapi sindrom dispepsia. Jurnal Health Sains, 2(7), 978–985. https://doi.org/10.46799/jhs.v2i7.230